AQST Earnings

AQST reported its earnings on 2026-05-13, showcasing a revenue of 14.45M against an estimate of 10.84M, resulting in a 33.27% surprise. The EPS was -0.07, surpassing the expected -0.14 by 50%. The stock experienced a 14.53% price change on the earnings day and a -0.97% change over the next five days, reflecting market reactions to the results.

Following AQST's earnings announcement on 2026-05-13, the stock price moved by 14.53% on the day of the release. Over the subsequent five days, it saw a -0.97% change. Historically, AQST's stock price tends to shift by an average of -0.48% in the 10 days leading up to earnings and 2.18% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate AQST's annual revenue to reach 13.98M, while the EPS is projected at -0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AQST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AQST's stock price typically moves by -0.48% in the 10 days before its earnings and 2.18% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.17 and revenue of 13.98M.

The earnings call summary and Q&A reveal strong financial performance, strategic product development, and promising market strategies. Anaphylm's launch preparation and international expansion plans are positive indicators, supported by stable financials and a robust cash position. The Q&A highlights management's proactive approach to market challenges and confidence in regulatory timelines, despite some uncertainties. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.